RETRACTED: Mesenchymal Stem/Stromal Cells as a Vehicle for Cytokine Delivery: An Emerging Approach for Tumor Immunotherapy
Pro-inflammatory cytokines can effectively be used for tumor immunotherapy, affecting every step of the tumor immunity cycle. Thereby, they can restore antigen priming, improve the effector immune cell frequencies in the tumor microenvironment (TME), and eventually strengthen their cytolytic functio...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2021-08-01
|
| Series: | Frontiers in Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fmed.2021.721174/full |
| _version_ | 1797224953080184832 |
|---|---|
| author | Ehsan Razeghian Ria Margiana Ria Margiana Ria Margiana Supat Chupradit Dmitry O. Bokov Dmitry O. Bokov Walid Kamal Abdelbasset Walid Kamal Abdelbasset Faroogh Marofi Siavash Shariatzadeh Foad Tosan Mostafa Jarahian |
| author_facet | Ehsan Razeghian Ria Margiana Ria Margiana Ria Margiana Supat Chupradit Dmitry O. Bokov Dmitry O. Bokov Walid Kamal Abdelbasset Walid Kamal Abdelbasset Faroogh Marofi Siavash Shariatzadeh Foad Tosan Mostafa Jarahian |
| author_sort | Ehsan Razeghian |
| collection | DOAJ |
| description | Pro-inflammatory cytokines can effectively be used for tumor immunotherapy, affecting every step of the tumor immunity cycle. Thereby, they can restore antigen priming, improve the effector immune cell frequencies in the tumor microenvironment (TME), and eventually strengthen their cytolytic function. A renewed interest in the anticancer competencies of cytokines has resulted in a substantial promotion in the number of trials to address the safety and efficacy of cytokine-based therapeutic options. However, low response rate along with the high toxicity associated with high-dose cytokine for reaching desired therapeutic outcomes negatively affect their clinical utility. Recently, mesenchymal stem/stromal cells (MSCs) due to their pronounced tropism to tumors and also lower immunogenicity have become a promising vehicle for cytokine delivery for human malignancies. MSC-based delivery of the cytokine can lead to the more effective immune cell-induced antitumor response and provide sustained release of target cytokines, as widely evidenced in a myriad of xenograft models. In the current review, we offer a summary of the novel trends in cytokine immunotherapy using MSCs as a potent and encouraging carrier for antitumor cytokines, focusing on the last two decades' animal reports. |
| first_indexed | 2024-03-12T02:38:27Z |
| format | Article |
| id | doaj.art-94cd182116de4b82bac75c921d6a6a2a |
| institution | Directory Open Access Journal |
| issn | 2296-858X |
| language | English |
| last_indexed | 2024-04-24T14:01:18Z |
| publishDate | 2021-08-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Medicine |
| spelling | doaj.art-94cd182116de4b82bac75c921d6a6a2a2024-04-03T12:39:47ZengFrontiers Media S.A.Frontiers in Medicine2296-858X2021-08-01810.3389/fmed.2021.721174721174RETRACTED: Mesenchymal Stem/Stromal Cells as a Vehicle for Cytokine Delivery: An Emerging Approach for Tumor ImmunotherapyEhsan Razeghian0Ria Margiana1Ria Margiana2Ria Margiana3Supat Chupradit4Dmitry O. Bokov5Dmitry O. Bokov6Walid Kamal Abdelbasset7Walid Kamal Abdelbasset8Faroogh Marofi9Siavash Shariatzadeh10Foad Tosan11Mostafa Jarahian12Human Genetics Division, Medical Biotechnology Department, National Institute of Genetics Engineering and Biotechnology (NIGEB), Tehran, IranDepartment of Anatomy, Faculty of Medicine, Universitas Indonesia, Jakarta, IndonesiaCipto Mangunkusumo Hospital, The National Referral Hospital, Central Jakarta, IndonesiaMaster's Programme Biomedical Sciences, Faculty of Medicine, Universitas Indonesia, Jakarta, IndonesiaDepartment of Occupational Therapy, Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai, ThailandInstitute of Pharmacy, Sechenov First Moscow State Medical University, Moscow, RussiaLaboratory of Food Chemistry, Federal Research Center of Nutrition, Biotechnology and Food Safety, Moscow, RussiaDepartment of Health and Rehabilitation Sciences, College of Applied Medical Sciences, Prince Sattam bin Abdulaziz University, Al Kharj, Saudi ArabiaDepartment of Physical Therapy, Kasr Al-Aini Hospital, Cairo University, Giza, Egypt0Immunology Research Center (IRC), Tabriz University of Medical Sciences, Tabriz, Iran1Department of Pharmacology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran2Student Research Committee, Semnan University of Medical Sciences, Semnan, Iran3Toxicology and Chemotherapy Unit (G401), German Cancer Research Center, Heidelberg, GermanyPro-inflammatory cytokines can effectively be used for tumor immunotherapy, affecting every step of the tumor immunity cycle. Thereby, they can restore antigen priming, improve the effector immune cell frequencies in the tumor microenvironment (TME), and eventually strengthen their cytolytic function. A renewed interest in the anticancer competencies of cytokines has resulted in a substantial promotion in the number of trials to address the safety and efficacy of cytokine-based therapeutic options. However, low response rate along with the high toxicity associated with high-dose cytokine for reaching desired therapeutic outcomes negatively affect their clinical utility. Recently, mesenchymal stem/stromal cells (MSCs) due to their pronounced tropism to tumors and also lower immunogenicity have become a promising vehicle for cytokine delivery for human malignancies. MSC-based delivery of the cytokine can lead to the more effective immune cell-induced antitumor response and provide sustained release of target cytokines, as widely evidenced in a myriad of xenograft models. In the current review, we offer a summary of the novel trends in cytokine immunotherapy using MSCs as a potent and encouraging carrier for antitumor cytokines, focusing on the last two decades' animal reports.https://www.frontiersin.org/articles/10.3389/fmed.2021.721174/fullmesenchymal stem/stromal cellscytokinetumor-immunotherapygene therapycytokine delivery |
| spellingShingle | Ehsan Razeghian Ria Margiana Ria Margiana Ria Margiana Supat Chupradit Dmitry O. Bokov Dmitry O. Bokov Walid Kamal Abdelbasset Walid Kamal Abdelbasset Faroogh Marofi Siavash Shariatzadeh Foad Tosan Mostafa Jarahian RETRACTED: Mesenchymal Stem/Stromal Cells as a Vehicle for Cytokine Delivery: An Emerging Approach for Tumor Immunotherapy Frontiers in Medicine mesenchymal stem/stromal cells cytokine tumor-immunotherapy gene therapy cytokine delivery |
| title | RETRACTED: Mesenchymal Stem/Stromal Cells as a Vehicle for Cytokine Delivery: An Emerging Approach for Tumor Immunotherapy |
| title_full | RETRACTED: Mesenchymal Stem/Stromal Cells as a Vehicle for Cytokine Delivery: An Emerging Approach for Tumor Immunotherapy |
| title_fullStr | RETRACTED: Mesenchymal Stem/Stromal Cells as a Vehicle for Cytokine Delivery: An Emerging Approach for Tumor Immunotherapy |
| title_full_unstemmed | RETRACTED: Mesenchymal Stem/Stromal Cells as a Vehicle for Cytokine Delivery: An Emerging Approach for Tumor Immunotherapy |
| title_short | RETRACTED: Mesenchymal Stem/Stromal Cells as a Vehicle for Cytokine Delivery: An Emerging Approach for Tumor Immunotherapy |
| title_sort | retracted mesenchymal stem stromal cells as a vehicle for cytokine delivery an emerging approach for tumor immunotherapy |
| topic | mesenchymal stem/stromal cells cytokine tumor-immunotherapy gene therapy cytokine delivery |
| url | https://www.frontiersin.org/articles/10.3389/fmed.2021.721174/full |
| work_keys_str_mv | AT ehsanrazeghian retractedmesenchymalstemstromalcellsasavehicleforcytokinedeliveryanemergingapproachfortumorimmunotherapy AT riamargiana retractedmesenchymalstemstromalcellsasavehicleforcytokinedeliveryanemergingapproachfortumorimmunotherapy AT riamargiana retractedmesenchymalstemstromalcellsasavehicleforcytokinedeliveryanemergingapproachfortumorimmunotherapy AT riamargiana retractedmesenchymalstemstromalcellsasavehicleforcytokinedeliveryanemergingapproachfortumorimmunotherapy AT supatchupradit retractedmesenchymalstemstromalcellsasavehicleforcytokinedeliveryanemergingapproachfortumorimmunotherapy AT dmitryobokov retractedmesenchymalstemstromalcellsasavehicleforcytokinedeliveryanemergingapproachfortumorimmunotherapy AT dmitryobokov retractedmesenchymalstemstromalcellsasavehicleforcytokinedeliveryanemergingapproachfortumorimmunotherapy AT walidkamalabdelbasset retractedmesenchymalstemstromalcellsasavehicleforcytokinedeliveryanemergingapproachfortumorimmunotherapy AT walidkamalabdelbasset retractedmesenchymalstemstromalcellsasavehicleforcytokinedeliveryanemergingapproachfortumorimmunotherapy AT farooghmarofi retractedmesenchymalstemstromalcellsasavehicleforcytokinedeliveryanemergingapproachfortumorimmunotherapy AT siavashshariatzadeh retractedmesenchymalstemstromalcellsasavehicleforcytokinedeliveryanemergingapproachfortumorimmunotherapy AT foadtosan retractedmesenchymalstemstromalcellsasavehicleforcytokinedeliveryanemergingapproachfortumorimmunotherapy AT mostafajarahian retractedmesenchymalstemstromalcellsasavehicleforcytokinedeliveryanemergingapproachfortumorimmunotherapy |